<DOC>
	<DOCNO>NCT01645189</DOCNO>
	<brief_summary>The objective study determine safety efficacy weekly dose idursulfase-beta 0.5mg/kg administer intravenous ( IV ) infusion Hunter syndrome patient &lt; 6 year old .</brief_summary>
	<brief_title>Safety Efficacy Hunterase</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>1 . The patient diagnosis Hunter syndrome base upon biochemical criterion : measure plasma , leukocytes , fibroblast , deficiency iduronate2sulfatase ( I2S ) enzyme activity â‰¤ 10 % low limit normal range That correspond one following : normal enzyme activity level one sulfatase Confirmed MPS2 genetic test result show clinical symptoms/ visible sign MPS2 2 . &lt; 6 year old male 3 . Patients able comply study requirement 4 . The patient 's parent ( ) , patient 's legal guardian must give voluntary write consent participate study 1 . The patient tracheostomy 2 . The patient know severe hypersensitivity shock component idursulfase 3 . The patient receive treatment another investigational therapy within 30 day prior enrollment 4 . History stem cell transplant 5 . The patient know severe hypersensitivity shock component test drug ( excipient etc )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hunter syndrome</keyword>
	<keyword>idursulfase-beta</keyword>
	<keyword>Hunterase</keyword>
	<keyword>GC1111</keyword>
</DOC>